Cargando…

1570. Association Between Vancomycin Area Under the Curve (AUC) and Nephrotoxicity

BACKGROUND: It is unclear whether increased vancomycin area under the curve (AUC) contributes to acute kidney injury (AKI) risk. METHODS: This retrospective cohort study was undertaken to determine whether vancomycin AUC > 550 is associated with a higher rate of AKI than an AUC < 550. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poston-Blahnik, Anna, Moenster, Ryan P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810180/ http://dx.doi.org/10.1093/ofid/ofz360.1434

Ejemplares similares

1391. Vancomycin Area Under the Curve (AUC) to Predict Nephrotoxicity: A Systematic Review and Meta-Analysis of Observational Studies
por: Aljefri, Doaa, et al.
Publicado: (2018)

1097. A Comparison of Area-Under Curve (AUC)-Guided vs Trough-Guided Monitoring of Vancomycin and Its Impact on Nephrotoxicity: A Systematic Review and Meta-analysis
por: Lim, Ashley Shiyuan, et al.
Publicado: (2021)

Characteristics and calculations of paired vancomycin measurements for determination of 24-h area-under-curve (AUC)
por: Deng, Yutao, et al.
Publicado: (2023)

775. Comparison of Initial Vancomycin Costs and Target Attainment Between Trough- and 24-Hour Area Under the Concentration–Time Curve (AUC24)-Guided Dosing
por: Laurent, David, et al.
Publicado: (2019)

599. Association between Vancomycin AUC and Clinical Failure in Patients with Streptococcal Bacteremia
por: Aycock, Anna C, et al.
Publicado: (2022)

1326. Vancomycin Area Under the Concentration-Time Curve (AUC) Estimation Using a Bayesian Approach Versus First-Order Pharmacokinetic Equations: A Pilot Study
por: Pearson, Jeffrey, et al.
Publicado: (2020)

Implementation of a Vancomycin AUC Monitoring Program: Peaks and Pitfalls
por: Kassamali, Zahra, et al.
Publicado: (2017)

598. Area under the curve-guided vancomycin monitoring and risk of nephrotoxicity in non-Staphylococcus aureus infections: A case-control study
por: Mazewski, Douglas, et al.
Publicado: (2022)

Predicting the Area under the Plasma Concentration-Time Curve (AUC) for First Dose Vancomycin Using First-Order Pharmacokinetic Equations
por: Sujjavorakul, Kritsaporn, et al.
Publicado: (2023)

Evaluation of a Novel Glucose Area Under the Curve (AUC) Monitoring System: Comparison with the AUC by Continuous Glucose Monitoring
por: Ugi, Satoshi, et al.
Publicado: (2016)

1090. Does calculation method matter for targeting vancomycin AUC?
por: Chang, Jack, et al.
Publicado: (2021)

349. The impact of Vancomycin dosing by area under the curve over minimal inhibitory concentration (AUC/MIC) versus Trough levels on cumulative Vancomycin dosage and incidence of Acute Kidney Injury (AKI) in patients admitted to intensive care units (ICU)
por: Sahu, Aniruddha, et al.
Publicado: (2023)

1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury
por: Avedissian, Sean N, et al.
Publicado: (2019)

1571. Evaluation of a Single Post First Dose Vancomycin Level to Achieve a Goal Vancomycin AUC
por: Hurley, Evan, et al.
Publicado: (2019)

A Monocentric Retrospective Study of AUC/MIC Ratio of Vancomycin Associated with Clinical Outcomes and Nephrotoxicity in Patients with Enterococcal Infections
por: Katip, Wasan, et al.
Publicado: (2021)

1552. Correlation Between Vancomycin Serum Trough Concentrations and Area Under the Curve in Pediatric Patients
por: Weaver, Krista, et al.
Publicado: (2019)

2567. Clinical Outcomes of Vancomycin Area-Under-the-Curve Monitoring: A Quasi-Experimental Study
por: Viteri, Alina, et al.
Publicado: (2023)

Successful Treatment of Invasive MRSA Infections in Children Using Area Under the Vancomycin Concentration-Time Curve Divided by the Minimum Inhibitory Concentration (AUC/MIC) to Measure Vancomycin Exposure
por: Chiang, Leslie, et al.
Publicado: (2021)

Comparison of Outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Vancomycin vs. Non-Vancomycin Anti-MRSA Therapy
por: Stoneking, Carolyn, et al.
Publicado: (2017)

1107. Vancomycin AUC Dosing: Is One Concentration in the Hand Worth Two in the Bush?
por: Spivey, Justin, et al.
Publicado: (2021)

Impact of Vancomycin Serum Trough Concentrations and Vancomycin AUC/MIC on Vancomycin Response, In-Hospital Outcomes and Acute Kidney Injury in Pediatric Staphylococcus aureus Pneumonia
por: McNeil, Jonathon, et al.
Publicado: (2017)

1642. Vancomycin AUC(24) Estimation Using First Order Pharmacokinetic Methods in Pediatric Patients
por: Wallace, Katie L, et al.
Publicado: (2023)

1645. Predicting Vancomycin Area Under the Curve by Bayesian-Guided Dosing in Pediatric Patients
por: Shin, Donghyun, et al.
Publicado: (2023)

1328. Vancomycin exposure and utilization following implementation of an AUC-guided monitoring guideline in children
por: Quraishi, Ruquaya, et al.
Publicado: (2020)

2193. Vancomycin AUC:MIC Monitoring: Transitioning Safely from Inpatient to Outpatient Monitoring via OPAT
por: Campion, Maureen, et al.
Publicado: (2023)

1424. Examining the Relationship Between Vancomycin Area Under the Concentration–Time Curve and Serum Trough Levels in Adults with Presumed or Documented Staphylococcal Infections
por: Clark, Laura, et al.
Publicado: (2018)

A modified Wald interval for the area under the ROC curve (AUC) in diagnostic case-control studies
por: Kottas, Martina, et al.
Publicado: (2014)

Educational Resource Review: The case for AUC dosing of vancomycin
Publicado: (2020)

1415. Implementation and Validation of a Vancomycin AUC/MIC Calculator and Dosing Protocol at a Large Community Hospital
por: Seddon, Megan, et al.
Publicado: (2018)

1599. AUC24 Vancomycin Bayesian-Based Dosing: Increasing Therapeutic Target Attainment with Decreased TDM Cost
por: Sabourenkov, Paul E, et al.
Publicado: (2019)

2558. Association of Vancomycin-Induced Acute Kidney Injury with Trough Versus AUC Monitoring in Patients Receiving Extended Durations of Therapy
por: Pitcock, C Tyler, et al.
Publicado: (2023)

67. Agreement Among Bayesian Dosing Software for Calculating Vancomycin Area Under the Curve
por: Pineda, Ross, et al.
Publicado: (2021)

1596. Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)
por: Alosaimy, Sara, et al.
Publicado: (2019)

2226. Trough- Versus AUC-Based Vancomycin Monitoring for Treatment of Acute Pulmonary Exacerbations of Adult Cystic Fibrosis Patients
por: Smith, Darrell, et al.
Publicado: (2023)

1091. Validation of an Allometrically Scaled Body Weight Equation to Predict Vancomycin Clearance and Guide 24-Hour Vancomycin AUC Dosing in Obese Patients
por: Footer, Brent, et al.
Publicado: (2021)

1327. Vancomycin Dosing by AUC(24)/MIC in Comparison to Traditional Trough Dosing in Office Infusion Centers (OICs)
por: Luu, Quyen, et al.
Publicado: (2020)

The Nephrotoxicity of Vancomycin
por: Filippone, EJ, et al.
Publicado: (2017)

1576. Delaying the Start of Maintenance Vancomycin After a Loading Dose to Avoid a High 0–24h AUC
por: Lee, Judy T Y, et al.
Publicado: (2019)

2877. Influence of vancomycin AUC monitoring on acute kidney injury in a large quasi-experimental study of over 3000 patients
por: Gregory, Eric, et al.
Publicado: (2023)

Vancomycin-Associated Tubular Casts and Vancomycin Nephrotoxicity
por: Tantranont, Ngoentra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ca8mbbmuf6rjsfku3ebt5lmemp